Disitamab vedotin (RC48) combined with PD-1 inhibitors in locally advanced or metastatic urothelial carcinoma: clinical outcomes and prognostic factors from a multicenter real-world study

Background and objectivesThe combination of disitamab vedotin (RC48) with PD-1 inhibitors has shown synergistic potential in preclinical studies for treating advanced urothelial carcinoma (UC). Nevertheless, real-world evidence regarding its clinical efficacy and safety profile remains limited. This...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Xin Chang Zou, Lie Yu Xu, Yu Yang Yuan, Gu Yue Zhang, Jian Biao Huang, Tao Zeng
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Frontiers Media S.A. 2026-04-01
Sarja:	Frontiers in Immunology
Aiheet:	disitamab vedotin locally advanced or metastatic urothelial carcinoma mixed patient population PD-1 inhibitor real-world study
Linkit:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1815591/full
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!